• Something wrong with this record ?

A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers

E. Thunnissen, H. Blaauwgeers, F. Filipello, B. Lissenberg-Witte, Y. Minami, M. Noguchi, JL. Quesne, MG. Papotti, DB. Flieder, G. Pelosi, I. Sansano, S. Berezowska, A. Ryška, L. Brcic, N. Motoi, Y. Nakatani, C. Kuempers, P. Hofman, V. Hofman, VG....

. 2025 ; 199 (-) : 108060. [pub] 20241219

Language English Country Ireland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25010410

OBJECTIVES: Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification. MATERIALS AND METHODS: A retrospective case-control study was conducted on small NMA pT1N0M0 cases with a 5-year follow-up. Seventy cases were reviewed by 42 pulmonary pathologists first according to the WHO classification and after tutorial according to a modified classification. A third round was conducted based on feedback from 41 peers of previous rounds. Additionally, orthogonal biomarker analysis was performed. RESULTS: In the first two rounds, 42 pathologists from 13 countries assessed all 70 cases, while 36 pathologists evaluated 41 non-unanimous cases in the third round. Kappa values for invasiveness increased in rounds 1, 2, and 3 to 0.27, 0.45 and 0.62, respectively. In contrast to low variation in total tumor size measurements (6 %), a marked increase in invasive tumor size variation was observed (42 %), which was associated with high uncertainty. In the third round 10 cases were non-invasive, all without recurrence. The modified classification showed in the 3rd round marked reduction of the variation in pT staging compared to the current WHO classification. Proliferation rate, tumor mutational burden, and transcriptomic profiles supported the distinction between invasive cases and non-invasive cases of the modified classification. CONCLUSION: The modified classification demonstrates essentially higher reproducibility compared to the current WHO classification in NMA. The modified classification proves valuable in identifying low-risk lesions that are entirely non-invasive, and is supported by biomarker analysis.

Center for Personalized Medicine Heidelberg Heidelberg Germany

Dept of Epidemiology and Data Science Amsterdam UMC VU University Amsterdam the Netherlands

Dept of Pathology Aarhus University Aarhus Denmark

Dept of Pathology Amsterdam UMC VU University Amsterdam the Netherlands

Dept of Pathology Canisius Wilhelmina Hospital Nijmegen the Netherlands

Dept of Pathology Charles University ESP Hradec Kralove Czech Republic

Dept of Pathology CRUK Beatson Cancer Research Institute Glasgow Scotland UK

Dept of Pathology Department of Histopathology Queen Elizabeth University Hospital Glasgow Scotland UK

Dept of Pathology Department of Oncology and Hemato Oncology University of Milan Milan Italy

Dept of Pathology Erasmus Medical Center Rotterdam the Netherlands

Dept of Pathology Fondazione Poliambulanza Hospital Institute Brescia Brescia Italy

Dept of Pathology Fox Chase Cancer Center Philadelphia PA USA

Dept of Pathology Hospital Universitari Vall d'Hebron Barcelona Spain

Dept of Pathology HUS Helsinki University Hospital Helsinki Finland

Dept of Pathology International University of Health and Welfare Mita Hospital Tokyo Japan

Dept of Pathology Jichi Medical University Tochigi Japan

Dept of Pathology LabPON Hengelo the Netherlands

Dept of Pathology Lausanne University Hospital and University of Lausanne Lausanne Switzerland

Dept of Pathology Maggiore Hospital University of Bologna Bologna Italy

Dept of Pathology Meander Medisch Centrum Amersfoort the Netherlands

Dept of Pathology Medical University of Graz Graz Austria

Dept of Pathology Mount Sinai Medical Center New York NY USA

Dept of Pathology Naritatomisato Tokushukai Hospital Chiba Japan

Dept of Pathology National Hospital Organization Ibarakihigashi National Hospital Tokai Japan

Dept of Pathology National Institute of Pneumology M Nasta Bucharest Romania

Dept of Pathology OLVG LAB BV Amsterdam the Netherlands

Dept of Pathology Padova University Hospital Padova Italy

Dept of Pathology Rijnstate Ziekenhuis Arnhem the Netherlands

Dept of Pathology Saitama Cancer Center Saitama Japan

Dept of Pathology San Raffaele Scientific Institute Milan Italy

Dept of Pathology School of Cancer Sciences University of Glasgow Scotland UK

Dept of Pathology St James's Hospital Dublin Ireland

Dept of Pathology St Olavs Hospital Trondheim University Hospital Trondheim Norway

Dept of Pathology Universitätsklinikum Schleswig Holstein Campus Lübeck Lübeck Germany

Dept of Pathology University Clinic Golnik Golnik Slovenia

Dept of Pathology University College London Cancer Institute London United Kingdom

Dept of Pathology University Medical Center Groningen Groningen the Netherlands

Dept of Pathology University of California San Francisco CA USA

Dept of Pathology University of Turin Turin Italy

Dept of Pathology UZ Leuven Leuven Belgium

Dept of Pathology Yale School of Medicine New Haven CT USA

Dept of Pathology Yokosuka Kyosai Hospital Yokosuka Japan

Dept Pathologie DNA St Antoniusziekenhuis Nieuwegein the Netherlands

IHU RespirERA FHU OncoAge Nice University Hospital Center Laboratory of Clinical and Experimental Pathology Nice France

Institute of Pathology Heidelberg University Hospital Heidelberg Germany

Norwegian University of Science and Technology Trondheim Norway

PathoPulse Søborg Denmark

Translational Lung Research Center Heidelberg Germany

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010410
003      
CZ-PrNML
005      
20250429134728.0
007      
ta
008      
250415e20241219ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lungcan.2024.108060 $2 doi
035    __
$a (PubMed)39793325
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Thunnissen, Erik $u Dept. of Pathology, Amsterdam UMC, VU University, Amsterdam, the Netherlands. Electronic address: e.thunnissen@amsterdamumc.nl
245    12
$a A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers / $c E. Thunnissen, H. Blaauwgeers, F. Filipello, B. Lissenberg-Witte, Y. Minami, M. Noguchi, JL. Quesne, MG. Papotti, DB. Flieder, G. Pelosi, I. Sansano, S. Berezowska, A. Ryška, L. Brcic, N. Motoi, Y. Nakatani, C. Kuempers, P. Hofman, V. Hofman, VG. Dale, G. Rossi, F. Ambrosi, D. Matsubara, Y. Ishikawa, B. Weynand, F. Calabrese, F. Pezzuto, I. Kern, S. Nicholson, A. Mutka, S. Dacic, MB. Beasley, G. Arrigoni, W. Timens, M. Ooft, M. Brinkhuis, N. Bulkmans, R. Britstra, W. Vreuls, KD. Jones, JH. von der Thüsen, H. Hager, S. Perner, D. Moore, DG. Leonte, S. Al-Janabi, A. Schønau, O. Neumann, K. Kluck, I. Ourailidis, M. Ball, J. Budczies, D. Kazdal, A. Stenzinger
520    9_
$a OBJECTIVES: Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification. MATERIALS AND METHODS: A retrospective case-control study was conducted on small NMA pT1N0M0 cases with a 5-year follow-up. Seventy cases were reviewed by 42 pulmonary pathologists first according to the WHO classification and after tutorial according to a modified classification. A third round was conducted based on feedback from 41 peers of previous rounds. Additionally, orthogonal biomarker analysis was performed. RESULTS: In the first two rounds, 42 pathologists from 13 countries assessed all 70 cases, while 36 pathologists evaluated 41 non-unanimous cases in the third round. Kappa values for invasiveness increased in rounds 1, 2, and 3 to 0.27, 0.45 and 0.62, respectively. In contrast to low variation in total tumor size measurements (6 %), a marked increase in invasive tumor size variation was observed (42 %), which was associated with high uncertainty. In the third round 10 cases were non-invasive, all without recurrence. The modified classification showed in the 3rd round marked reduction of the variation in pT staging compared to the current WHO classification. Proliferation rate, tumor mutational burden, and transcriptomic profiles supported the distinction between invasive cases and non-invasive cases of the modified classification. CONCLUSION: The modified classification demonstrates essentially higher reproducibility compared to the current WHO classification in NMA. The modified classification proves valuable in identifying low-risk lesions that are entirely non-invasive, and is supported by biomarker analysis.
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x patologie $x klasifikace $x diagnóza $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a retrospektivní studie $7 D012189
650    12
$a Světová zdravotnická organizace $7 D014944
650    12
$a adenokarcinom plic $x patologie $x metabolismus $x klasifikace $x diagnóza $7 D000077192
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a staging nádorů $7 D009367
650    12
$a invazivní růst nádoru $7 D009361
650    _2
$a senioři $7 D000368
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a následné studie $7 D005500
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Blaauwgeers, Hans $u Dept. of Pathology, OLVG LAB BV, Amsterdam, the Netherlands
700    1_
$a Filipello, Federica $u Dept. of Pathology, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Lissenberg-Witte, Birgit $u Dept. of Epidemiology and Data Science, Amsterdam UMC, VU University, Amsterdam, the Netherlands
700    1_
$a Minami, Yuko $u Dept. of Pathology, National Hospital Organization Ibarakihigashi National Hospital, Tokai, Japan
700    1_
$a Noguchi, Masayuki $u Dept. of Pathology, Naritatomisato Tokushukai Hospital, Chiba, Japan
700    1_
$a Quesne, John Le $u Dept. of Pathology, School of Cancer Sciences, University of Glasgow, Scotland, UK; Dept. of Pathology, CRUK Beatson Cancer Research Institute, Glasgow, Scotland, UK; Dept. of Pathology, Department of Histopathology, Queen Elizabeth University Hospital, Glasgow, Scotland, UK
700    1_
$a Papotti, Mauro Giulio $u Dept. of Pathology, University of Turin, Turin, Italy
700    1_
$a Flieder, Douglas B $u Dept. of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA
700    1_
$a Pelosi, Giuseppe $u Dept. of Pathology, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
700    1_
$a Sansano, Irene $u Dept. of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
700    1_
$a Berezowska, Sabina $u Dept. of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
700    1_
$a Ryška, Aleš $u Dept. of Pathology, Charles University, ESP, Hradec Kralove, Czech Republic
700    1_
$a Brcic, Luka $u Dept. of Pathology, Medical University of Graz, Graz, Austria
700    1_
$a Motoi, Noriko $u Dept. of Pathology, Saitama Cancer Center, Saitama, Japan
700    1_
$a Nakatani, Yukio $u Dept. of Pathology, Yokosuka Kyosai Hospital, Yokosuka, Japan
700    1_
$a Kuempers, Christiane $u Dept. of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
700    1_
$a Hofman, Paul $u IHU RespirERA, FHU OncoAge, Nice University Hospital Center, Laboratory of Clinical and Experimental Pathology, Nice, France
700    1_
$a Hofman, Veronique $u IHU RespirERA, FHU OncoAge, Nice University Hospital Center, Laboratory of Clinical and Experimental Pathology, Nice, France
700    1_
$a Dale, Vibeke Grotnes $u Dept. of Pathology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Norwegian University of Science and Technology, Trondheim, Norway
700    1_
$a Rossi, Giulio $u Dept. of Pathology, Fondazione Poliambulanza Hospital Institute, Brescia, Brescia, Italy
700    1_
$a Ambrosi, Francesca $u Dept. of Pathology, Maggiore Hospital, University of Bologna, Bologna, Italy
700    1_
$a Matsubara, Daisuke $u Dept. of Pathology, Jichi Medical University, Tochigi, Japan
700    1_
$a Ishikawa, Yuichi $u Dept. of Pathology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan
700    1_
$a Weynand, Birgit $u Dept. of Pathology, UZ Leuven, Leuven, Belgium
700    1_
$a Calabrese, Fiorella $u Dept. of Pathology, Padova University Hospital, Padova, Italy
700    1_
$a Pezzuto, Federica $u Dept. of Pathology, University Clinic Golnik, Golnik, Slovenia
700    1_
$a Kern, Izidor $u Dept. of Pathology, St. James's Hospital, Dublin, Ireland
700    1_
$a Nicholson, Siobhan $u Dept. of Pathology, HUS Helsinki University Hospital, Helsinki, Finland
700    1_
$a Mutka, Aino $u Dept. of Pathology, Yale School of Medicine, New Haven, CT, USA
700    1_
$a Dacic, Sanja $u Dept. of Pathology, Mount Sinai Medical Center, New York, NY, USA
700    1_
$a Beasley, Mary Beth $u Dept. of Pathology, University Medical Center Groningen, Groningen, the Netherlands
700    1_
$a Arrigoni, Gianluigi $u Dept. of Pathology, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Timens, Wim $u Dept. of Pathology, Rijnstate Ziekenhuis, Arnhem, the Netherlands
700    1_
$a Ooft, Marc $u Dept. of Pathology, LabPON, Hengelo, the Netherlands
700    1_
$a Brinkhuis, Mariel $u Dept. Pathologie-DNA, St. Antoniusziekenhuis, Nieuwegein, the Netherlands
700    1_
$a Bulkmans, Nicole $u Dept. of Pathology, Meander Medisch Centrum, Amersfoort, the Netherlands
700    1_
$a Britstra, Rieneke $u Dept. of Pathology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands
700    1_
$a Vreuls, Willem $u Dept. of Pathology, University of California, San Francisco, CA, USA
700    1_
$a Jones, Kirk D $u Dept. of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands
700    1_
$a von der Thüsen, Jan H $u Dept. of Pathology, Aarhus University, Aarhus, Denmark
700    1_
$a Hager, Hendrik $u Dept. of Pathology, University College London Cancer Institute, London, United Kingdom
700    1_
$a Perner, Sven $u Dept. of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
700    1_
$a Moore, David $u Dept. of Pathology, University of California, San Francisco, CA, USA
700    1_
$a Leonte, Diana Gabriela $u Dept. of Pathology, National Institute of Pneumology "M. Nasta", Bucharest, Romania
700    1_
$a Al-Janabi, Shaimaa $u Dept. of Pathology, OLVG LAB BV, Amsterdam, the Netherlands
700    1_
$a Schønau, Andreas $u PathoPulse, Søborg, Denmark
700    1_
$a Neumann, Olaf $u Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Center for Personalized Medicine (ZPM) Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
700    1_
$a Kluck, Klaus $u Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Center for Personalized Medicine (ZPM) Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
700    1_
$a Ourailidis, Iordanis $u Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Center for Personalized Medicine (ZPM) Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
700    1_
$a Ball, Markus $u Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Center for Personalized Medicine (ZPM) Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
700    1_
$a Budczies, Jan $u Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Center for Personalized Medicine (ZPM) Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
700    1_
$a Kazdal, Daniel $u Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Center for Personalized Medicine (ZPM) Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
700    1_
$a Stenzinger, Albrecht $u Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Center for Personalized Medicine (ZPM) Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
773    0_
$w MED00003160 $t Lung cancer $x 1872-8332 $g Roč. 199 (20241219), s. 108060
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39793325 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134724 $b ABA008
999    __
$a ok $b bmc $g 2311642 $s 1247491
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 199 $c - $d 108060 $e 20241219 $i 1872-8332 $m Lung cancer $n Lung Cancer $x MED00003160
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options